These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 209808)

  • 1. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME; Dische S; Anderson P; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy related to misonidazole: incidence and pathology.
    Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
    Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
    Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD; Strike TA
    Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
    Schwade JG; Makuch RW; Strong JM; Glatstein E
    Cancer Treat Rep; 1982 Sep; 66(9):1743-50. PubMed ID: 6288238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
    Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentration of misonidazole and peripheral neuropathy.
    Marten TR
    Am J Clin Oncol; 1982 Apr; 5(2):239-40. PubMed ID: 6283876
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
    Workman P
    Cancer Clin Trials; 1980; 3(3):237-51. PubMed ID: 7438321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of misonidazole during continuous low dose rate irradiation.
    Fu KK; Hurst S; Begg AC; Brown JM
    Cancer Clin Trials; 1980; 3(3):257-65. PubMed ID: 7438323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.
    Dische S; Saunders MI; Lee ME; Adams GE; Flockhart IR
    Br J Cancer; 1977 May; 35(5):567-79. PubMed ID: 861146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone.
    Wasserman TH; Phillips TL; Van Raalte G; Urtasun R; Partington J; Koziol D; Schwade JG; Gangji D; Strong JM
    Br J Radiol; 1980 Feb; 53(626):172-3. PubMed ID: 6245744
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical experience with daily doses of misonidazole (author's transl)].
    Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
    Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of misonidazole.
    Notter G; Rylander U; Turesson I
    Strahlentherapie; 1980; 156(10):714-8. PubMed ID: 7434379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Misonidazole neuropathy.
    Paulson OB; Melgaard B; Hansen HS; Kamieniecka Z; Køhler O; Hansen JM; Pedersen AG; Tang X; Trojaborg W
    Acta Neurol Scand Suppl; 1984; 100():133-6. PubMed ID: 6091392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurotoxicity of misonidazole: pooling of data from five centres.
    Disch S; Saunders MI; Anderson P; Urtasun RC; Karcher KH; Kogelnik HD; Bleehen N; Phillips TL; Wasserman TH
    Br J Radiol; 1978 Dec; 51(612):1023-4. PubMed ID: 216455
    [No Abstract]   [Full Text] [Related]  

  • 19. The response of human tumour metastases to radiation and misonidazole.
    Dawen PJ; Peckham MJ; Steel GG
    Br J Cancer Suppl; 1978 Jun; 3():290-6. PubMed ID: 277247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.